Mobile

A 6-week open label cross-over study with 2 different daily doses of Minirin® oral lyophilisate (120 μg and 240 μg) and 2 different daily doses of Minirin® tablet (0.2 mg and 2 x 0.2 mg) in children a...

Mise à jour : Il y a 4 ans
Référence : EUCTR2004-000593-32

A 6-week open label cross-over study with 2 different daily doses of Minirin® oral lyophilisate (120 μg and 240 μg) and 2 different daily doses of Minirin® tablet (0.2 mg and 2 x 0.2 mg) in children and adolescents with primary nocturnal enuresis (PNE)

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To evaluate the preference of subjects for Minirin® oral lyophilisate treatment compared with Minirin® tablet treatment after 6 weeks.

Critère d'inclusion

  • Primary Nocturnal Enuresis

Liens